Company Details
Shaanxi YXchuang Biotechnology Co., Ltd
Palatin Technologies Inc. (NYSE: PT-141) announced today that it has shown positive results in a Phase I clinical trial of pT-141 for the treatment of sexual dysfunction in normal premenopausal women.
The trial included 32 healthy female volunteers and evaluated their response to pT-141 and placebo in response to visual stimuli. Pt-141 was found to be safe and resulted in a significantly greater improvement in vaginal blood flow than placebo users (P< 0.05).
role
Such antibiotics first affect the outer membrane of sensitive bacteria. Drug ring part of polypeptide amino and lipopolysaccharide in the outer membrane 2 valence cations combining site to produce electrostatic interaction, destroy the integrity of the outer membrane damage, fatty acid part of drugs to penetrate the outer membrane, thus increase the permeability of cell size, lead to intracytoplasmic phosphate, nucleosides and other small molecules to escape, straight die cause cell dysfunction. Gram-positive bacteria do not respond to such antibiotics because they have a thick cell wall that prevents drugs from entering the bacteria.